Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 1.00 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.52 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294757 | 1.00 | ERN1 (1.00) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL8958081 | 0.98 | ERN1 (0.96) | ERN1TLR2TLR1TLR6TRIM24 | |
| Ethylene SCHEMBL11602187 | 0.94 | ERN1 (0.88) | ERN1TLR2TLR1TLR6TRIM24 | |
| Ethylenediamine SCHEMBL11775933 | 0.92 | ERN1 (0.85) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL11775930 | 0.90 | ERN1 (0.81) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL4437283 | 0.84 | ERN1 (0.71) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL454110 | 0.84 | ERN1 (0.72) | ERN1TDP1 | |
| SCHEMBL419950 | 0.83 | ERN1 (0.76) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL8698633 | 0.80 | ERN1 (0.65) | ERN1TLR2TLR1TLR6LMNA | |
| SCHEMBL26095419 | 0.78 | ERN1 (0.62) | ERN1TLR2TLR1TLR6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080106-A | Oleanolic acid acylhydrazone derivative and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12502661-B2 | Catalysts for synthesizing cyclic carbonates, preparation methods and uses thereof | ANHUI CONCH MATERIAL TECHNOLOGY CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20250352989-A1 | CATALYSTS FOR SYNTHESIZING CYCLIC CARBONATES, PREPARATION METHODS AND USES THEREOF | ANHUI CONCH MATERIAL TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| EP-4539855-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Borah, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2023244775-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022261466-A1 | LIPID CRYSTALLINE COMPOSITIONS WITH ENHANCED STABILITY FOR TOPICAL DELIVERY OF ACTIVE AGENT COMBINATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-12-15 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114025847-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352989-A1 | CATALYSTS FOR SYNTHESIZING CYCLIC CARBONATES, PREPARATION METHODS AND USES THEREOF | PBRM1, POLL, PPOX | ERN1 3491/4885TLR2 665/4885TLR1 301/4885 |
| US-12502661-B2 | Catalysts for synthesizing cyclic carbonates, preparation methods and uses thereof | PBRM1, POLL, PPOX | ERN1 3491/4885TLR2 665/4885TLR1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.